Report: Prospective COVID-19 treatments at risk of shortage
A report by Premier, Inc., indicates dramatic spikes in demand for two antimalarial drugs that may influence positive COVID-19 outcomes. According to the report, demand for chloroquine and hydroxychloroquine increased significantly between March 1-17, placing them at risk of supply shortages. Some of the drugs’ makers, including Teva and Bayer, have since announced that they will donate millions of tablets for these drugs to hospitals for further testing.
Related News Articles
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…